Global Health valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
57.01×————
8.00×————
6.77×————
Enterprise multiples
7.00×————
33.50×————
44.78×————
Yield
1.8%————
−0.4%————
Reference — adjusted share basis
₹1,180.00————
₹20.70₹20.71₹17.92₹17.80₹12.14
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MEDANTA₹1,180.00

Global Health Ltd.

· Pharma & Health
₹ CrorePeersMAXHEALTHAPOLLOHOSPFORTISGLAXOANTHEMAJANTPHARMIPCALABABBOTINDIAMcap ₹31,705 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————57.01
P/B————8.00
P/Sales————6.77
Enterprise Multiples
EV/Sales————7.00
EV/EBITDA————33.50
EV/EBIT————44.78
Yield
Earnings Yield %————1.75
FCF Yield %————-0.39
Reference — adjusted share basis
Price (FY-end close, adj.)————1,180.00
EPS (adj.)12.1417.8017.9220.7120.70
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.